Stoke Therapeutics, Inc.

STOK Nasdaq SEC CIK 1623526
Follow Stoke Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $11.3M +5.9% vs same quarter last year
Net income −$73.6M −92% vs same quarter last year
EPS, diluted −$1.08 −66.2% vs same quarter last year
Operating cash flow −$62.7M −106.4% vs same quarter last year
Revenue by quarter
$22.6M
$158.6M
$13.8M
$10.6M
$1.4M
$6.2M
$9.3M
$11.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$184.4M−$6.9M
FY24$36.6M−$89M
FY23$8.8M−$104.7M
FY22$12.4M−$101.1M
FY21-−$85.8M
FY20-−$52.2M
FY19-−$32.3M
FY18-−$12.5M
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1500%−1000%−500%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−11.2%−3.7%
FY24−277.3%−243.4%
FY23−1307.2%−1192.5%
FY22−841.2%−814.7%
FY21--
FY20--
FY19--
FY18--
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$100M−$50M$0$50MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$44.9M
FY24−$87.1M
FY23−$82.7M
FY22−$35.8M
FY21−$68.1M
FY20−$43.3M
FY19−$32.7M
FY18−$11.9M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Stoke Therapeutics
  • Healthcare median
−1500%−1000%−500%0%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearStoke TherapeuticsHealthcare median
FY25−3.7%−30.6%
FY24−243.4%−47%
FY23−1192.5%−58%
FY22−814.7%−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%